Clinical data for AML samples
FAB subtype . | No. of samples studied . | Patient age, y . | WBC count, × 109/L (% blasts) . | Cytogenetics . |
|---|---|---|---|---|
| M1 | 2 | 50-66 | 6-80 (35-100) | t(8;20) |
| M2 | 4 | 25-52 | 11-78 (38-50) | t(7;11), Inv(16), t(7;16)(q32,q23), del17(q21.1) |
| M4 + M4eos | 5 | 29-66 | 23-305 (55-90) | Inv(16), +14, +22, del15(q12,q23) |
| M5 + M5a | 3 | 20-47 | 47-168 (72-92) | Inv(16) |
| MDS/AML | 1 | 70 | 2 (50) | Inv(16) |
FAB subtype . | No. of samples studied . | Patient age, y . | WBC count, × 109/L (% blasts) . | Cytogenetics . |
|---|---|---|---|---|
| M1 | 2 | 50-66 | 6-80 (35-100) | t(8;20) |
| M2 | 4 | 25-52 | 11-78 (38-50) | t(7;11), Inv(16), t(7;16)(q32,q23), del17(q21.1) |
| M4 + M4eos | 5 | 29-66 | 23-305 (55-90) | Inv(16), +14, +22, del15(q12,q23) |
| M5 + M5a | 3 | 20-47 | 47-168 (72-92) | Inv(16) |
| MDS/AML | 1 | 70 | 2 (50) | Inv(16) |
FAB indicates French-American-British; MDS, myelodysplastic syndrome.